{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:10:33Z","timestamp":1788232233772,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s13555-022-00791-1","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:03:52Z","timestamp":1660896232000},"page":"2145-2160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"von Kiedrowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schenck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Ertner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Fait","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8347-7426","authenticated-orcid":false,"given":"Mike","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"5","key":"791_CR1","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1111\/jdv.16003","volume":"34","author":"M de Bruin-Weller","year":"2020","unstructured":"de Bruin-Weller M, et al. The patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study in Europe and Canada. J Eur Acad Dermatol Venereol. 2020;34(5):1026\u201336.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"791_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrd4624","volume":"15","author":"NA Gandhi","year":"2016","unstructured":"Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"10023","key":"791_CR3","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","volume":"387","author":"S Weidinger","year":"2016","unstructured":"Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109\u201322.","journal-title":"Lancet"},{"issue":"1","key":"791_CR4","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/jdv.13813","volume":"31","author":"MA Radtke","year":"2017","unstructured":"Radtke MA, et al. Prevalence and comorbidities in adults with psoriasis compared to atopic eczema. J Eur Acad Dermatol Venereol. 2017;31(1):151\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"791_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.2147\/CLEP.S315888","volume":"13","author":"K Hagenstr\u00f6m","year":"2021","unstructured":"Hagenstr\u00f6m K, et al. Prevalence and Medications of Atopic Dermatitis in Germany: Claims Data Analysis. Clin Epidemiol. 2021;13:593\u2013602.","journal-title":"Clin Epidemiol"},{"issue":"1","key":"791_CR6","first-page":"151","volume":"19","author":"T Werfel","year":"2021","unstructured":"Werfel T, et al. Update \u201cSystemic treatment of atopic dermatitis\u201d of the S2k-guideline on atopic dermatitis. J Dtsch Dermatol Ges. 2021;19(1):151\u201368.","journal-title":"J Dtsch Dermatol Ges"},{"key":"791_CR7","doi-asserted-by":"crossref","unstructured":"Villeneuve S et al. Disease severity and control in adults with a history of moderate and\/or severe atopic dermatitis: results from a large patient and physician survey in the United Kingdom, Germany, and France. Value Health, 2016. 19: p. A596 (PSY120).","DOI":"10.1016\/j.jval.2016.09.1436"},{"issue":"1","key":"791_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.15919","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"791_CR9","unstructured":"Sanofi. Dupixent\u00ae Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf. Accessed 16 Mar 2022."},{"issue":"5","key":"791_CR10","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1007\/s13555-021-00586-w","volume":"11","author":"KA Papp","year":"2021","unstructured":"Papp KA, et al. Practical management of patients with atopic dermatitis on dupilumab. Dermatol Ther (Heidelb). 2021;11(5):1805\u201328.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"791_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.jaip.2020.12.059","volume":"9","author":"M Boguniewicz","year":"2021","unstructured":"Boguniewicz M, et al. Dupilumab improves asthma and sinonasal outcomes in adults with moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021;9(3):1212-1223.e6.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10086","key":"791_CR12","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","volume":"389","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287\u2013303.","journal-title":"Lancet"},{"key":"791_CR13","doi-asserted-by":"crossref","unstructured":"Stingeni L et al. Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience. J Eur Acad Dermatol Venereol, 2022.","DOI":"10.1111\/jdv.18141"},{"key":"791_CR14","doi-asserted-by":"crossref","unstructured":"Sears AV et al. Real-world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single-centre, prospective 1-year observational cohort study of the first 100 patients treated. 2021. 184(4): p. 755\u2013757.","DOI":"10.1111\/bjd.19631"},{"issue":"4","key":"791_CR15","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1111\/jdv.17094","volume":"35","author":"C Patruno","year":"2021","unstructured":"Patruno C, et al. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. J Eur Acad Dermatol Venereol. 2021;35(4):958\u201364.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl","key":"791_CR16","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","volume":"60","author":"JM Hanifin","year":"1980","unstructured":"Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Dermatovener (Stockh). 1980;60(Suppl):44\u20137.","journal-title":"Acta Dermatovener (Stockh)"},{"issue":"5","key":"791_CR17","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1111\/bjd.13662","volume":"172","author":"YA Leshem","year":"2015","unstructured":"Leshem YA, et al. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353\u20137.","journal-title":"Br J Dermatol"},{"issue":"2","key":"791_CR18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2340\/00015555-1632","volume":"94","author":"C Apfelbacher","year":"2014","unstructured":"Apfelbacher C, et al. Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol. 2014;94(2):163\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"791_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/cod.13113","volume":"80","author":"CJ Apfelbacher","year":"2019","unstructured":"Apfelbacher CJ, et al. Chronic hand eczema in Germany: 5-year follow-up data from the CARPE registry. Contact Dermatitis. 2019;80(1):45\u201353.","journal-title":"Contact Dermatitis"},{"issue":"3","key":"791_CR20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/jdv.17956","volume":"36","author":"L Stingeni","year":"2022","unstructured":"Stingeni L, et al. Patient-reported outcomes in adult atopic dermatitis are useful in both clinical trials and real-life clinical practice. J Eur Acad Dermatol Venereol. 2022;36(3):326\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"791_CR21","doi-asserted-by":"crossref","unstructured":"Kirsten, N., et al., Which PASI Outcome Is Most Relevant to the Patients in Real-World Care? Life (Basel), 2021. 11(11).","DOI":"10.3390\/life11111151"},{"issue":"1","key":"791_CR22","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin M, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12(1):48\u201357.","journal-title":"J Dtsch Dermatol Ges"},{"key":"791_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.5414\/ALX02262E","volume":"5","author":"D Siegels","year":"2021","unstructured":"Siegels D, et al. Status report on the atopic dermatitis registry TREATgermany. Allergol Select. 2021;5:274\u201386.","journal-title":"Allergol Select"},{"issue":"2","key":"791_CR24","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1080\/09546634.2020.1866741","volume":"32","author":"M de Bruin-Weller","year":"2021","unstructured":"de Bruin-Weller M, et al. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study. J Dermatolog Treat. 2021;32(2):164\u201373.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"791_CR25","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1111\/jdv.17203","volume":"35","author":"N Mohr","year":"2021","unstructured":"Mohr N, et al. Cost-of-illness of atopic dermatitis in Germany: data from dermatology routine care. J Eur Acad Dermatol Venereol. 2021;35(6):1346\u201356.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"791_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdv.15792","volume":"34","author":"N Zander","year":"2020","unstructured":"Zander N, et al. Atopic dermatitis shows significant cutaneous comorbidity: results from large-scale investigations in the working population. J Eur Acad Dermatol Venereol. 2020;34(1):135\u201341.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"791_CR27","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00105-021-04885-3","volume":"72","author":"A Langenbruch","year":"2021","unstructured":"Langenbruch A, et al. Quality of care for patients with atopic dermatitis in Germany-no improvements in indicators after ten years. Hautarzt. 2021;72(12):1079\u201389.","journal-title":"Hautarzt"},{"issue":"6","key":"791_CR28","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/jdv.12154","volume":"28","author":"A Langenbruch","year":"2014","unstructured":"Langenbruch A, et al. Quality of health care of atopic eczema in Germany: results of the national health care study AtopicHealth. J Eur Acad Dermatol Venereol. 2014;28(6):719\u201326.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"791_CR29","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1111\/jdv.15074","volume":"32","author":"S Steinke","year":"2018","unstructured":"Steinke S, et al. Measurement of healthcare quality in atopic dermatitis\u2014development and application of a set of quality indicators. J Eur Acad Dermatol Venereol. 2018;32(12):2237\u201343.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00791-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00791-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T23:11:50Z","timestamp":1700953910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00791-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["791"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00791-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"16 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}